Ipsen has announced that it will acquire U.S.-based Kartos Therapeutics. The transaction includes an upfront payment of $450 million and up to $1.3 billion in development, regulatory, and sales milestones, bringing the total potential value to up to $1.75 billion. Deal Highlights $450M upfront; total potential value of up to $1.75B Navtemadlin: late-stage MDM2 inhibitor […]
AbbVie has announced that it will acquire Apogee Therapeutics, a biotech company focused on immunology and inflammatory diseases, in a cash transaction valued at approximately $10.9 billion. Through the acquisition, AbbVie will gain Apogee’s long-acting antibody pipeline, led by zumilokibart. Deal Highlights Transaction value of approximately $10.9 billion Purchase price of $135.11 per share Lead […]
GSK has announced that it will acquire oncology biotech Nuvalent in a $10.6 billion cash transaction. Nuvalent is developing targeted therapies for non-small cell lung cancer, including its lead candidates zidesamtinib and neladalkib, which are currently under FDA review. Deal Overview $10.6 billion cash transaction Purchase price of $124 per share Lead candidates include zidesamtinib […]
Pfizer has entered into a global oncology collaboration with Innovent Biologics worth up to $10.5 billion. The agreement covers 12 early-stage oncology programs, including antibody-drug conjugates and multispecific antibodies. Innovent will receive $650 million upfront, with the remaining value tied to development, regulatory, and commercial milestones. Collaboration Overview 12 early-stage oncology programs 8 Innovent-originated candidates […]
Eli Lilly and Company has announced acquisitions of three vaccine developers – Curevo, LimmaTech Biologics, and Vaccine Company – in deals valued at up to approximately $3.8 billion combined. The move signals Lilly’s renewed focus on infectious disease prevention and vaccine innovation. Acquisition Overview Curevo | up to $1.5B Developing a next-generation shingles vaccine candidate, […]
Bristol Myers Squibb and Hengrui Pharma have announced a global strategic collaboration and licensing agreement worth up to $15.2 billion. The collaboration covers 13 early-stage programmes across oncology, hematology, and immunology. Rather than a single asset licensing deal, this partnership combines multiple candidates and newly discovered programmes within a broader co-development framework. Partnership highlights 13 […]
UCB has announced an agreement to acquire U.S.-based Neurona Therapeutics for up to $1.15 billion, extending its long-established epilepsy franchise into regenerative medicine and advanced therapies. Neurona’s lead asset, NRTX-1001, is a neuronal cell therapy being developed in Phase I/II trials for drug-resistant mesial temporal lobe epilepsy. Designed as a single-dose approach aimed at restoring […]
Eli Lilly and Company has announced an agreement to acquire Houston-based biotech CrossBridge Bio in a deal valued at up to $300 million, adding an early-stage dual-payload ADC platform to its oncology pipeline. Founded in 2023, CrossBridge is a preclinical company built around technology originating from UTHealth Houston. Key points Total deal value of up […]
Gilead Sciences has announced an agreement to acquire Germany-based clinical-stage biotech Tubulis in a deal valued at up to $5 billion, expanding its oncology pipeline through next-generation antibody-drug conjugate, or ADC, technology. The acquisition adds Tubulis’ lead programme TUB-040, along with its proprietary Tubutecan linker-payload technology and broader ADC platform. The transaction also builds on […]
Last week, Greenstaff Life Sciences attended BIOCHINA2026 in Suzhou, China. Hiroshi Yamaguchi, Head of Greenstaff Life Sciences, and Summer Wang, Director of Greenstaff Medical China, attended the conference and engaged in discussions and exchanges across the life sciences community. Across the event, strong discussions took place around innovation, collaboration, and the future of biotech in […]
- 1
- 2